Metronidazole ointment - Braintree Laboratories
Alternative Names: BLI-1300Latest Information Update: 25 Dec 2021
At a glance
- Originator Braintree Laboratories
- Class Antibacterials; Antiprotozoals; Nitroimidazoles; Radiosensitisers; Skin disorder therapies; Small molecules
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Crohn's disease
Most Recent Events
- 25 Oct 2012 Braintree Laboratories terminates a phase II trial in Chrohn's disease in USA (NCT01442363)
- 23 Nov 2011 Phase-II clinical trials in Crohn's disease in USA (Topical)